Societal CDMO Dividenda 2024

Detalji o dividendama

Razumevanje dividendnih isplata od Societal CDMO

Dividende od Societal CDMO su deo profita kompanije koji se distribuira akcionarima. One su ključni indikator finansijskog zdravlja kompanije i atraktivnosti za investitore. Dividende pružaju investitorima stabilan izvor prihoda, pored dobiti koja se možda može ostvariti prodajom akcija po višoj ceni od kupovne.

Poređenje iz godine u godinu

Analiza isplata dividendi od Societal CDMO tokom godina može istaći profitabilnost i stabilnost kompanije. Konstantno ili rastuće isplate dividendi mogu ukazivati na finansijski zdravu kompaniju sa predvidivim profitom, dok fluktuacije ili smanjenja dividendi mogu signalizirati osnovne finansijske ili operativne izazove.

Uticaj na investicije

Isplate dividendi od Societal CDMO su suštinski faktor za investitore orijentisane na prihod. Robusna isplata dividendi može povećati privlačnost akcije i pružiti redovni prihod pored potencijalnih kapitalnih dobitaka. Ona može takođe pokazati poverenje kompanije u njene buduće profite i time biti značajan faktor za odlučivanje o investicijama.

Interpretacija fluktuacija dividendi

Promene u dividendama od Societal CDMO mogu proistići iz promena u profitima kompanije, finansijskoj politici ili strategijama reinvestiranja. Povećanje dividendi često signalizira finansijsku stabilnost, dok smanjenje može ukazivati na potrebu da se sačuva gotovina ili da se profiti reinvestiraju radi podsticanja rasta, pri čemu svaki scenario ima različite posledice za investitore.

Societal CDMO Aktienanalyse

Шта ради Societal CDMO?

Recro Pharma Inc. is a company operating in the biopharmaceutical industry, specializing in the development and marketing of innovative therapeutics. The company is based in Malvern, Pennsylvania, USA, and was founded in 2007. The history of Recro Pharma Inc. dates back to 1985, when the company was founded as ReceptoPharm. In 2008, it was renamed Recro Pharma Inc. to emphasize its focus on pharmaceutical activities. Since then, the company has made significant progress, including successful clinical trials and the introduction of innovative products. Recro Pharma follows a business model based on the development of therapeutics in the areas of pain management and anesthesia. The company aims to create solutions to alleviate pain in patients and improve their quality of life. Recro Pharma's goal is to bring high-quality products to the market that are distinguished by excellent safety, efficacy, and patient tolerance. Recro Pharma's product range currently includes two main areas. Firstly, the company has launched its medication Meloxicam for pain treatment in adults. Secondly, it has developed and distributes a portfolio of anesthesia-related therapeutics through its subsidiary Lumendi LLC. Meloxicam is a non-steroidal anti-inflammatory drug used for pain relief in adults. The medication is available in various forms such as tablets and capsules and is used in both hospital and outpatient care. Lumendi LLC specializes in the development and distribution of anesthesia-related therapeutics. The company's products include those for intubation and muscle relaxation in surgical procedures, as well as anesthesia for pain management. Lumendi's goal is to create innovative solutions to improve medical practice and shorten hospital stays. Recro Pharma Inc. aims to expand its product range through the development of further innovative solutions. The company continues to invest in research and development to develop new products and strengthen its position in the market. In 2020, Recro Pharma Inc. received FDA approval for the product IV Meloxicam. This is an intravenous form of the drug Meloxicam used for pain treatment in adults. This is a significant milestone for the company as it is now able to offer an alternative form of the medication. Recro Pharma Inc. has established itself as a significant player in the biopharmaceutical industry. The company aspires to further strengthen its position in the market and create innovative solutions to improve medical practice. With its high-quality products, Recro Pharma contributes to alleviating patients' pain and improving their quality of life. Societal CDMO je jedna od najpopularnijih kompanija na Eulerpool.com.

Često postavljana pitanja o Societal CDMO akciji

Kolika je dividenda koju isplaćuje Societal CDMO?

U poslednjih 12 meseci, Societal CDMO je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Societal CDMO će verovatno isplatiti dividendu od 0 USD.

Kolika je dividendna prinosa za Societal CDMO?

Dividendski prinos od Societal CDMO trenutno iznosi .

Kada Societal CDMO isplaćuje dividendu?

Societal CDMO isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Koliko je sigurna dividenda od Societal CDMO?

Societal CDMO je isplaćivao dividendu svake godine u poslednjih 0 godina.

Kolika je dividenda kompanije Societal CDMO?

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

U kom sektoru se nalazi Societal CDMO?

Societal CDMO se svrstava u sektor 'Zdravlje'.

Wann musste ich die Aktien von Societal CDMO kaufen, um die vorherige Dividende zu erhalten?

Da biste primili poslednju dividendu od Societal CDMO od 11. 8. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 11. 8. 2024..

Kada je Societal CDMO poslednji put isplatio dividendu?

Isplata poslednje dividende izvršena je 11. 8. 2024..

Kolika je bila dividenda od Societal CDMO u godini 2023?

U godini 2023 kompanija Societal CDMO je isplatila 0 USD kao dividende.

U kojoj valuti Societal CDMO isplaćuje dividendu?

Dividende od Societal CDMO se isplaćuju u USD.